Skip to main content

Biohaven Ltd 8-K, filed Nov 16, 2026

Biohaven Ltd. (BHVN)

8-K 2026-11-16 For: 2026-11-16
View Original
Added on November 16, 2026

About this 8-K

Biohaven Ltd filed this 8-K on November 16, 2026.

Biohaven Ltd. reports the FDA instructed it to pause new opakalim enrollment under a September 4, 2026 partial clinical hold; BHV-1300 entered Phase 3, while BHV-1400 Phase 3 initiation is planned for 2026. AI summary

Items reported

  • Item 7.01: Regulation FD disclosure
  • Item 9.01: Financial statements and exhibits